First-Quarter 2025 First Quarter Overall Net Sales $698.0M | 0.4% Diluted Earnings Per Share: $1.23 Adjusted Diluted Earnings Per Share: $1.45 "I am pleased to report we delivered a solid first quarter as both revenues and adjusted-diluted EPS exceeded our first quarter guidance. We are capitalizing on areas of strength and making progress to improve margins and returns on invested capital. As such, we expect our positive trends to continue and remain confident in our ability to execute and achieve our guid ...

West Pharmaceutical Services, Inc. (WST) delivered adjusted first-quarter 2025 earnings per share (EPS) of $1.45, which declined 7.1% year over year. The figure, however, topped the Zacks Consensus Estimate by 18.9%.The adjustments include expenses related to the amortization of acquisition-related intangible assets, among others.GAAP EPS for the quarter was $1.23, reflecting a decline of 20.6% from the year-ago figure. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)WST’s Revenues ...

Financial Performance - First-quarter 2025 net sales were $698.0 million, a 0.4% increase compared to $695.4 million in the same period last year[5][17]. - Adjusted-diluted EPS for the first quarter was $1.45, down from $1.56 in the prior year, while reported-diluted EPS was $1.23 compared to $1.55[5][17]. - The company raised its full-year 2025 net sales guidance to a range of $2.945 billion to $2.975 billion, up from the previous range of $2.875 billion to $2.905 billion[5][10]. - Full-year 2025 adjusted-diluted EPS guidance was increased to a range of $6.15 to $6.35, up from $6.00 to $6.20, incorporating estimated tariff costs of $20 to $25 million[5][10]. - The guidance for reported diluted EPS for 2025 is projected between $5.86 and $6.06, reflecting a decrease of 12.4% to 9.4% compared to 2024[23]. Cash Flow and Profitability - Operating cash flow for the first quarter was $129.4 million, reflecting a 9.5% increase, while free cash flow rose to $58.1 million from $27.6 million in the prior year[8]. - The company reported an operating profit of $107.0 million for Q1 2025, adjusted to $125.0 million after accounting for restructuring and other charges[20]. - Operating cash flow for Q1 2025 was $129.4 million, up from $118.2 million in Q1 2024, demonstrating improved cash generation[26]. - Free cash flow increased to $58.1 million in Q1 2025, compared to $27.6 million in the same period last year, highlighting enhanced financial flexibility[26]. Segment Performance - Proprietary Products segment net sales grew by 0.6% to $563.0 million, with organic net sales growth of 2.4% driven by demand for self-injection device platforms[4][19]. - Contract-Manufactured Products segment net sales declined by 0.7% to $135.0 million, although organic net sales grew by 0.8%[7][19]. Shareholder Actions - The company repurchased 550,281 shares for $133.5 million at an average price of $242.63 during the first quarter[9]. Expenses and Charges - The company recorded $17.8 million in restructuring charges during Q1 2025, primarily related to severance and depreciation costs[20]. - Capital expenditures for the first quarter were $71.3 million, a decrease of 21.3% compared to the same period last year[8]. Balance Sheet and Inventory - The company’s total debt remained stable at $202.6 million as of March 31, 2025, with equity slightly increasing to $2,683.1 million[28]. - Cash and cash equivalents decreased to $404.2 million as of March 31, 2025, down from $484.6 million at the end of 2024[28]. - Inventories increased to $388.7 million as of March 31, 2025, compared to $377.0 million at the end of 2024, indicating potential growth in production or sales[28]. Profit Margins - The gross profit margin for the first quarter was 33.2%, slightly up from 33.1% in the same period last year[19].

Executive Leadership Changes - Bernard J. Birkett has announced his intention to retire from his position as Chief Financial Officer (CFO) of West Pharmaceutical Services, Inc. The company has initiated a search for his successor [2][7] - Birkett has been with West since June 2018 and has played a critical role in navigating challenges such as the global pandemic and the emergence of GLP-1s [2][3] - Shane Campbell has been appointed as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025. He brings extensive global management experience from his previous roles [3][4] Company Performance - West Pharmaceutical Services generated $2.89 billion in net sales in its fiscal year 2024, indicating strong financial performance [10] - The company is recognized as a leader in providing innovative, high-quality injectable solutions and services, supporting the delivery of life-saving medicines [9][10] Future Outlook - The company is focused on continuing its growth and success through its Proprietary Products strategy, leveraging the experience of new leadership [4][5]

- Conference Call Scheduled for 9 a.m. EDT Today -EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend.First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%. Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year. Adjusted-diluted EPS of $1.45, compared to $ ...

West Pharmaceutical Services (WST) is scheduled to release first-quarter 2025 results on April 24, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 4.00%. WST’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.33%.Q1 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $686.5 million, indicating a decline of 1.3% from the year-ago period’s level. The consensus mark for ear ...

West Pharmaceutical Services (WST) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on April 24, 2025, might help the stock move higher if these key numbers are b ...

Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting both established and emerging drug developers [4] - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices each year [4] Financial Performance - In fiscal year 2024, West generated $2.89 billion in net sales [5] - The company is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index [5] Upcoming Events - West will release its first-quarter financial results before the market opens on April 24, 2025, followed by a conference call at 9:00 a.m. Eastern Time [1] - A slide presentation will be available on the company's website on the day of the call, and a replay of the conference call and webcast will be accessible for approximately 90 days after the event [3]

Group 1 - The company West Pharmaceutical Services (NYSE: WST) has experienced a challenging year with noticeable underperformance against the index since May 2024 [1] - The analysis aims to identify high-quality businesses for long-term portfolio creation that can outperform the market [1]

Core Viewpoint - West Pharmaceutical Services, Inc. announced a second-quarter 2025 dividend of $0.21 per share, reflecting the company's commitment to returning value to shareholders [1]. Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting both established and emerging drug developers [2]. - The company employs over 10,000 team members across 50 sites, including 25 manufacturing facilities globally, delivering over 41 billion components and devices annually [2]. - In fiscal year 2024, West generated $2.89 billion in net sales and is listed on the New York Stock Exchange (NYSE: WST) as well as included in the Standard & Poor's 500 index [3].